实测与估算肾小球滤过率及不良健康结局风险
该回顾性队列研究纳入瑞典斯德哥尔摩6174名成人,中位随访5.9年,发现mGFR 60较90 mL/min/1.73 m2与全因死亡和肾衰竭风险升高相关。eGFRcr-cys与mGFR的死亡关联最接近,eGFRcr低估而eGFRcys高估死亡风险。
要点
- mGFR 60较90 mL/min/1.73 m2与全因死亡和肾衰竭风险升高相关。
- eGFRcr-cys与mGFR的死亡关联最接近。
- eGFRcr低估而eGFRcys高估mGFR与死亡的关联。
核心结论
- 在瑞典成人中,mGFR 60较90 mL/min/1.73 m2与全因死亡和肾衰竭风险升高相关,支持当前60 mL/min/1.73 m2的CKD定义阈值。
- mGFR与死亡的关联最接近eGFRcr-cys,eGFRcr低估而eGFRcys高估死亡风险。
研究设计与样本
- 回顾性观察性队列研究,纳入2011年1月1日至2021年12月31日瑞典斯德哥尔摩6174名成人。
- 暴露为基于血浆碘海醇清除率测得的mGFR,以及基于肌酐、胱抑素C或两者计算的eGFR。
主要发现
- 中位随访5.9年期间,1977例(32%)死亡,426例(6.9%)发生需替代治疗的肾衰竭。
- 与mGFR 90 mL/min/1.73 m2相比,mGFR 60 mL/min/1.73 m2与全因死亡率升高相关(27.6 vs 22.4/1000人年;HR 1.21;95%CI 1.14-1.28)。
- mGFR 60 mL/min/1.73 m2与肾衰竭风险升高相关(1.2 vs 0.4/1000人年;HR 2.85;95%CI 2.06-3.94)。
- 全因死亡方面,eGFRcr-cys与mGFR的HR比值无显著差异(RHR 1.03;95%CI 0.96-1.10)。
- eGFRcr低估mGFR关联(RHR 0.87;95%CI 0.79-0.95),eGFRcys高估(RHR 1.17;95%CI 1.08-1.27)。
关键数值与推荐
- 支持当前60 mL/min/1.73 m2的GFR阈值用于定义慢性肾脏病。
- eGFRcr-cys较eGFRcr或eGFRcys更接近mGFR与死亡的关联。
临床怎么用
- 临床评估CKD相关死亡风险时,eGFRcr-cys可能较单用肌酐或胱抑素C更准确反映mGFR关联。
- mGFR 60 mL/min/1.73 m2可作为风险升高的参考阈值。
局限性
- 回顾性观察性设计,可能受残余混杂影响。
- 研究人群来自瑞典单中心,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Lower estimated glomerular filtration rate (eGFR) is associated with increased rates of death and kidney and cardiovascular events. Associations of measured GFR (mGFR) with outcomes remain unclear. OBJECTIVE: To quantify associations between mGFR and adverse clinical outcomes and to compare these with eGFR-based associations. DESIGN, SETTING, AND PARTICIPANTS: Retrospective observational cohort study of 6174 adults from Stockholm, Sweden, between January 1, 2011, and December 31, 2021. EXPOSURE: Measured GFR was obtained based on plasma clearance of intravenously administered iohexol (primary independent variable of interest). Estimated GFR was calculated with plasma creatinine (eGFRcr), cystatin C (eGFRcys), or both (eGFRcr-cys), using the Chronic Kidney Disease Epidemiology Collaboration 2021 and 2012 equations. MAIN OUTCOMES AND MEASURES: Primary outcomes were all-cause mortality and kidney failure with replacement therapy. Associations of each GFR measure with outcomes were evaluated using hazard ratios adjusted for age, sex, body mass index (calculated as weight in kilograms divided by height in meters squared), medical history, medications, and urine albumin to creatinine ratio. RESULTS: Of 6174 participants (median age, 59 years [IQR, 43-69]; 3686 [60%] were male and 2488 [40%] were female), 1977 (32%) died and 426 (6.9%) developed kidney failure with replacement therapy during a median follow-up of 5.9 years (IQR, 3.0-8.8 years). Compared with a baseline mGFR of 90 mL/min/1.73 m2, an mGFR of 60 mL/min/1.73 m2 was associated with higher rates of all-cause mortality (27.6 vs 22.4 per 1000 person-years; hazard ratio [HR], 1.21; 95% CI, 1.14-1.28) and kidney failure with replacement therapy (1.2 vs 0.4 per 1000 person-years; HR, 2.85; 95% CI, 2.06-3.94). For all-cause mortality, associations for eGFRcr-cys did not significantly differ from those for mGFR (ratio of HRs [RHRs] at 60 mL/min/1.73 m2, 1.03; 95% CI, 0.96-1.10), whereas eGFRcr underestimated the mGFR-based association (RHR, 0.87; 95% CI, 0.79-0.95) and eGFRcys overestimated it (RHR, 1.17; 95% CI, 1.08-1.27). CONCLUSIONS AND RELEVANCE: Among adults in Sweden, mGFR values of 60 mL/min/1.73 m2 were associated with higher rates of all-cause mortality and kidney failure compared with mGFR values of 90 mL/min/1.73 m2, supporting the current GFR threshold of 60 mL/min/1.73 m2 to define chronic kidney disease. Associations of mGFR with mortality were most closely represented by the association of eGFRcr-cys with mortality, whereas eGFRcr underestimated and eGFRcys overestimated mortality risk.
引用
- Fu EL, Créon A, Grams ME, et al. Measured and Estimated Glomerular Filtration Rates and Risk of Adverse Health Outcomes. JAMA. 2026. PMID: 42240159. doi:10.1001/jama.2026.9639
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。